Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations.
The standard of care for the treatment of depression involves pharmacologic therapy with selective serotonin reuptake inhibitors (SSRIs). Cognitive therapy is typically utilized in addition to a pharmacologic intervention. However, the benefits of the drugs used may be marginal compared with placebo yet the costs associated with their use continue to increase. One potential treatment for depression utilizes botulinum toxins. At the present time there is a small body of evidence supporting their use for depression, the potential efficacy and cost effectiveness of this treatment warrants further consideration including head to head clinical trials.
Beer
Kenneth
K
Esthetic, Surgical and General Dermatology Center, West Palm Beach, FL, USA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D001905:Botulinum Toxins